Cerivastatin: pharmacology of a novel synthetic and highly active HMG-CoA reductase inhibitor (Q41077310)

26 September 2017

title

Cerivastatin: pharmacology of a novel synthetic and highly active HMG-CoA reductase inhibitor (English)

1 reference

26 September 2017

1 reference

Bischoff H

1

1 reference

26 September 2017

Angerbauer R

2

1 reference

26 September 2017

Bender J

3

1 reference

26 September 2017

Bischoff E

4

1 reference

26 September 2017

Faggiotto A

5

1 reference

26 September 2017

Petzinna D

6

1 reference

26 September 2017

Pfitzner J

7

1 reference

26 September 2017

Porter MC

8

1 reference

26 September 2017

Schmidt D

9

1 reference

26 September 2017

Thomas G

10

1 reference

26 September 2017

publication date

1 November 1997

1 reference

26 September 2017

1 reference

26 September 2017

volume

135

1 reference

26 September 2017

issue

1

1 reference

26 September 2017

page(s)

119-130

1 reference

A receptor-mediated pathway for cholesterol homeostasis

26 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900188-3

Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900188-3

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900188-3

Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900188-3

Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900188-3

CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase: tissue-selective inhibition of sterol synthesis and hypolipidemic effect on various animal species

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900188-3

Regulatory role for hepatic low density lipoprotein receptors in vivo in the dog

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900188-3

Pharmacology of competitive inhibitors of HMG-CoA reductase.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900188-3

Lipid-lowering activity of atorvastatin and lovastatin in rodent species: triglyceride-lowering in rats correlates with efficacy in LDL animal models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900188-3

Purification and characterization of 3-hydroxy-3-methylglutaryl coenzyme A reductase from chicken liver

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900188-3

Mevalonic acid in human plasma: relationship of concentration and circadian rhythm to cholesterol synthesis rates in man

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900188-3

Determination of free, total, and esterified cholesterol by high-performance liquid chromatography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900188-3

A quantitative densitometric method for the rapid separation and quantitation of the major tissue and lipoprotein lipids by high-performance thin-layer chromatography. I. Sample preparation, chromatography, and densitometry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900188-3

Low Density Lipoprotein Receptors in Bovine Adrenal Cortex. II. Low Density Lipoprotein Binding to Membranes Prepared from Fresh Tissue*

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900188-3

Lovastatin inhibits gallstone formation in the cholesterol-fed prairie dog

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900188-3

Cerivastatin, a New Potent Synthetic HMG Co-A Reductase Inhibitor: Effect of 0.2 mg Daily in Subjects With Primary Hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900188-3

10.1016/S0021-9150(97)00188-3

7 January 2021

Identifiers

DOI

1 reference

26 September 2017

1 reference